Attached files

file filename
EX-99.1 - EX-99.1 - Alexza Pharmaceuticals Inc.d75966exv99w1.htm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 7, 2010 (September 7, 2010)
ALEXZA PHARMACEUTICALS, INC.
 
(Exact name of registrant as specified in its charter)
         
Delaware   000-51820   77-0567768
         
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
         
Alexza Pharmaceuticals, Inc.
   
2091 Stierlin Court
  94043
Mountain View, California
   
     
(Address of principal executive offices)
  (Zip Code)
Registrant’s telephone number, including area code: (650) 944-7000
 
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Section 7 — Regulation FD
Item 7.01.   Regulation FD Disclosure.
On September 7, 2010, Alexza Pharmaceuticals, Inc. issued a press release announcing that it will participate in two investor conferences in September 2010 at The New York Palace hotel in New York, New York, including (i) the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 14, 2010 at 3:40 p.m. ET and (ii) the JMP Securities Healthcare Conference on Monday, September 27, 2010 at 2:00 p.m. ET. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information presented under this Item 7.01 and attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Section 9 — Financial Statements and Exhibits
Item 9.01.   Financial Statements and Exhibits.
(d) Exhibits.
         
Exhibit Number   Description
  99.1    
Press Release titled “Alexza Pharmaceuticals to Present at Upcoming Healthcare Conferences” dated September 7, 2010.

 


 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Alexza Pharmaceuticals, Inc.
 
 
Date: September 7, 2010  By:   /s/ Thomas B. King    
    Thomas B. King   
    President and Chief Executive Officer   
 

 


 

INDEX TO EXHIBITS
         
Exhibit Number   Description
  99.1    
Press Release titled “Alexza Pharmaceuticals to Present at Upcoming Healthcare Conferences” dated September 7, 2010.